Abstract:Abstract Background: Androgen receptor signaling inhibitors (ARSIs), including abiraterone and enzalutamide, are widely used to treat prostate cancer. However, resistance inevitably develops, and subsequent treatment options remain limited. Prior studies of resistant tumors identified genetic mechanisms of ARSI resistance converging on AR, including its gene and enhancer amplifications, as well as mutations and structural variants involving the ligand-binding domain. Additionally, a phenotypic switch from AR-driven adenocarcinoma to AR-independent neuroendocrine carcinoma is well recognized and thought to be mediated by epigenetic reprogramming. Genomic analysis of paired metastatic biopsies before and after ARSIs offers a unique opportunity to systematically define resistance mechanisms, but such data are limited, in part due to difficulty obtaining serial biopsies. Methods: We obtained paired metastatic biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) before the initiation of an ARSI and at disease progression while on the ARSI. We performed whole-genome sequencing (WGS) and RNA-seq on these samples and conducted bioinformatic and statistical analyses contrasting pairs pre- vs. post-ARSI to search for genetic and transcriptomic alternations associated with ARSI resistance. Results: We generated WGS data for 45 paired biopsies and concurrent RNA-seq data for 35 pairs. WGS analysis identified further copy number gain in the genomic region spanning AR and its known upstream enhancer in multiple patients, driven by tandem duplications, and associated with increased AR expression. Overlaying publicly available chromatin immunoprecipitation sequencing data of transcription factors known to be important in prostate cancer (AR, FOXA1, and HOXB13) and the enhancer marker H3K27ac, we identified putative novel enhancers both upstream and downstream of AR and plan to further assess their effects on AR expression in cell lines. Paired WGS analysis also identified genes with mutations newly arising post-ARSI, yet with only limited recurrence suggesting intertumor heterogeneity. Interestingly, our paired RNA-seq analysis identified SSTR1, whose expression was consistently and significantly decreased in most ARSI-resistant samples. In a separate retrospective analysis of a cohort of 123 patients, we found that low SSTR1 expression was associated with worse overall survival, and patient survival was improved with post-biopsy ARSIs only when SSTR1 expression was high. SSTR1 encodes somatostatin receptor type 1, and its activation by endogenous somatostatin or exogenous somatostatin analogues exerts an anti-proliferative effect in cells expressing SSTR1, consistent with our observation of its downregulation in resistant tumors. Conclusions: Whole genome and transcriptome analysis of paired metastatic biopsies identified amplification of putative novel AR enhancers and decreased SSTR1 expression involved in ARSI resistance that warrant further investigation in additional patients and experimental systems. Citation Format: Xiaolin Zhu, Daniël Vis, Martin Sjöström, Raunak Shrestha, Jeroen Kneppers, Tesa Severson, Yanyun Zhu, Meng Zhang, Arian Lundberg, Thaidy Moreno Rodriguez, Alana Weinstein, Haolong Li, Adam Foye, Rahul Aggarwal, Andries M Bergman, Eric Small, Wilbert Zwart, David Quigley, Michiel van der Heijden, Felix Feng. Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr A029.

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

Abstract A029: Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer

Antiandrogen Treatment Induces Stromal Cell Reprogramming to Promote Castration Resistance in Prostate Cancer

Somatostatin receptor 1 ( SSTR1 ) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients

Resistance to second-generation androgen receptor antagonists in prostate cancer

Abstract 4557: A Novel Approach of Disrupting Androgen-Receptor Signaling for Prostate Cancer Intervention

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

PROTACs Targeting Androgen Receptor Signaling: Potential Therapeutic Agents for Castration-Resistant Prostate Cancer

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Abstract 3699: Identifying novel resistance biomarkers in circulating tumor cell-expressed transcriptomes of metastatic castration-resistant prostate cancer patients treated with androgen receptor signaling inhibitors

Developing New Targeting Strategy for Androgen Receptor Variants in Castration Resistant Prostate Cancer

Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer

Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries